# Optain

> Optain is a New York-based medical technology company bringing retinal imaging into primary care. It combines the FDA-cleared Resolve camera with clinician-based teleophthalmology grading in the U.S.; its Assure AI analysis products are offered in markets where authorized. Founded in 2023 on earlier Australian ophthalmology research, it raised a $26 million Series A in 2025 and acquired EyePACS to extend its screening network.

- **Founded:** 2023
- **Headquarters:** New York, United States
- **Founders:** Mingguang He (Co-founder and Chief Medical Officer), Jeff Dunkel (Co-founder and Chief Executive Officer), Zachary Tan (Co-founder and President), Jason Sun (Co-founder of predecessor Eyetelligence)
- **Products:** Resolve Fundus Camera, U.S. teleophthalmology service, Eyetelligence Assure and Assure+
- **Notable:** FDA 510(k) clearance for Resolve Fundus Camera on April 30, 2025., Raised a $26 million Series A led by Insight Partners in September 2025., Acquired EyePACS in November 2025; EyePACS reported 1.5 million patients screened historically.

## Products & services

- **Resolve Fundus Camera** — Portable, automatic retinal camera with FDA 510(k) clearance in the U.S.; captures images without routine dilation and supports clinical assessment, not autonomous diagnosis.
- **U.S. teleophthalmology service** — Professional grading of retinal images and coded reports returned to clinical records, strengthened by the EyePACS network.
- **Eyetelligence Assure and Assure+** — AI software for retinal disease screening and, in Assure+, cardiovascular risk assessment; availability depends on country and it is not for sale in the U.S.

## Achievements

- FDA 510(k) clearance for Resolve Fundus Camera on April 30, 2025.
- Raised a $26 million Series A led by Insight Partners in September 2025.
- Acquired EyePACS in November 2025; EyePACS reported 1.5 million patients screened historically.
- Reported 200 provider sites live globally and more than 1,000 planned deployments in November 2025.
- Named to Digital Health New York's Digital Health 100 for three consecutive years by 2026.

## Latest updates

- **2026-06** — MediWorks named Optain its exclusive AI integration partner for an FC162 fundus camera offering across DACH, the Nordics and the Netherlands.
- **2026-05** — Austrade profiled Optain’s expansion in Australia and its primary-care deployments.
- **2026-03** — Insight Partners profiled CEO Jeff Dunkel and Optain's frontline screening strategy.
- **2026-03** — Optain reported a third consecutive appearance on Digital Health New York's Digital Health 100.
- **2025-11** — Acquired EyePACS after two years of collaboration; reported 200 live provider sites globally.
- **2025-11** — Announced oculomics research with Monash University and Digital Health CRC.
- **2025-09** — Closed a $26 million Series A led by Insight Partners.

## Links

- Website: https://www.optainhealth.com/
- LinkedIn: https://www.linkedin.com/company/optainhealth

---

Profile page: https://yespress.io/optain
Published by YesPress — https://yespress.io
Last updated: 2026-09-29